Implementing the New EU Legislation on Advanced Therapy Medicinal Products
This article was originally published in RAJ Devices
The large number of people who attended the European Medicines Agency’s first workshop on advanced therapy medicinal products reflects the interest of stakeholders for this rapidly evolving field. Around 160 individuals from regulatory authorities, industry and academia attended the much anticipated meeting, which took place in London on 3 April, a month after having been postponed due to severe weather conditions. Delegates from the EMEA and representatives from the EMEA’s new Committee for Advanced Therapies presented the key implementation aspects surrounding the relevant legislation, Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products, which has been in force since 30 December 2008.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.